GM
GMAB.US Genmab AS
- Market cap
- USD 31.7B
- P/E
- 44.3x
- P/B
- 5.03x
- ROE
- 14.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GMAB.US undervalued?
Graham numberThe Graham number of Genmab AS cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genmab AS fundamental analysis
No fundamental analysis for Genmab AS yet.
Genmab AS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…
Full company profileGenmab AS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genmab AS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.82B | 2.37B | 3.03B | 5.37B | 10.1B | 8.42B | 14.5B | 16.5B | 21.5B | 3.72B | 4.32B |
| Gross Profit | 1.82B | 2.37B | 3.03B | 5.37B | 10.1B | 8.42B | 14.5B | 16.2B | 20.5B | 3.41B | 4.01B |
| Operating Income | 1.05B | 1.34B | 1.38B | 2.64B | 6.31B | 2.95B | 6.27B | 5.32B | 6.70B | 1.25B | 1.43B |
| EBITDA | 1.17B | 1.44B | 1.70B | 3.01B | 6.17B | 4.18B | 7.35B | 6.00B | 9.70B | 1.34B | 1.48B |
| Net Income | 1.19B | 1.10B | 1.47B | 2.17B | 4.76B | 2.96B | 5.45B | 4.35B | 7.84B | 964M | 931M |
| EPS | 1.92 | 1.78 | 2.37 | 3.40 | 7.22 | 4.48 | 8.26 | 6.60 | 12 | 1.54 | 1.50 |
| Balance Sheet | |||||||||||
| Total Assets | 5.24B | 6.60B | 8.46B | 15.1B | 21.1B | 24.6B | 30.1B | 35.3B | 45.8B | 12.8B | 12.9B |
| Total Liabilities | 412M | 331M | 447M | 1.10B | 2.02B | 2.43B | 2.84B | 3.68B | 9.11B | 7.01B | 6.60B |
| Shareholders' Equity | 4.83B | 6.27B | 8.01B | 14.0B | 19.1B | 22.2B | 27.3B | 31.6B | 36.7B | 5.83B | 6.33B |
| Cash & Short-term Investments | 3.92B | 5.42B | 6.11B | 11.0B | 16.1B | 19.3B | 22.3B | 28.1B | 21.1B | 1.71B | 1.86B |
| Total Debt | 61.6M | 0.00 | 0.00 | 181M | 319M | 425M | 597M | 770M | 1.03B | 5.43B | 5.20B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 328M | 1.59B | 1.01B | 1.33B | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B | 1.19B | 765M |
| Capital Expenditure | 33.1M | 88.5M | 477M | 111M | 307M | 252M | 317M | 376M | 187M | 37.0M | 25.4M |
| Free Cash Flow | 295M | 1.50B | 537M | 1.22B | 6.13B | 1.98B | 3.60B | 7.00B | 7.58B | 1.15B | 740M |
| Ratios | |||||||||||
| ROE | 24.6% | 17.6% | 18.4% | 15.4% | 24.9% | 13.3% | 20.0% | 13.8% | 21.4% | 16.5% | 14.7% |
| ROA | 22.7% | 16.7% | 17.4% | 14.3% | 22.5% | 12.0% | 18.1% | 12.3% | 17.1% | 7.5% | 7.2% |
| Net Profit Margin | 65.4% | 46.7% | 48.7% | 40.4% | 47.1% | 35.1% | 37.6% | 26.4% | 36.4% | 25.9% | 21.5% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.93x | 0.82x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genmab AS dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | DKK 280M | 0.42 | 5.1% |
| 2021 | DKK 135M | 0.20 | 4.6% |
| 2020 | DKK 115M | 0.17 | 2.4% |
| 2019 | DKK 9.00M | 0.01 | 0.4% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on May 1, 2018.
Who owns Genmab AS
- Insiders 0.00%
- Institutions 20.52%
- Public & others 79.48%
- Shares outstanding 617M
- Free float 589M
Top funds holding GMAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Biotechnology ETF | 4.31M | 0.70% | -0.34% | Oct 2026 |
| AllianceBernstein US L/C Growth Eqty MF | 3.95M | 0.64% | 0.00% | Jun 2026 |
| American Funds New Perspective A | 3.08M | 0.50% | 0.00% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 2.64M | 0.43% | 0.00% | Oct 2026 |
| Orbis SICAV Intl Eq Inv | 2.21M | 0.36% | -26.05% | Apr 2026 |
| Orbis SICAV Global Bal Instl Inv | 1.79M | 0.29% | 0.00% | Mar 2026 |
| Orbis Optimal (US$) Fund | 1.03M | 0.17% | +23.87% | Mar 2026 |
| Orbis Global Equity Investor | 978K | 0.16% | 0.00% | Jun 2026 |
| American Growth One D | 944K | 0.15% | +5.58% | Sep 2026 |
| AB American Growth AX USD | 937K | 0.15% | +5.14% | Sep 2026 |
| Orbis OEIC Global Balanced Fixed Fee | 743K | 0.12% | +9.39% | Apr 2026 |
| Pictet-Biotech P USD | 719K | 0.12% | +0.38% | Jul 2026 |
| Orbis Optimal SA USD | 587K | 0.10% | +15.62% | Mar 2026 |
| Federated Hermes Kaufmann R | 521K | 0.08% | 0.00% | Sep 2026 |
| Avantis International Equity ETF | 512K | 0.08% | 0.00% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 454K | 0.07% | 0.00% | Sep 2026 |
| Capital Group NewPers LUX Z | 364K | 0.06% | 0.00% | Jul 2026 |
| Federated Hermes Kaufmann Small Cap A | 350K | 0.06% | 0.00% | Sep 2026 |
| Franklin DynaTech Fund A | 350K | 0.06% | +18.06% | Sep 2026 |
| Russell Inv Tax-Managed US Large Cap S | 342K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding GMAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13.1M | 2.14% | +64.83% | Jun 2026 |
| Orbis Allan Gray Ltd | 11.4M | 1.85% | -12.05% | Jun 2026 |
| AllianceBernstein L.P. | 8.64M | 1.41% | -9.55% | Jun 2026 |
| Deerfield Management Co | 6.87M | 1.12% | +178.84% | Jun 2026 |
| Deep Track Capital, LP | 5.65M | 0.92% | +54.23% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 4.98M | 0.81% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.67M | 0.76% | +2.97% | Jun 2026 |
| Sofinnova Ventures | 4.05M | 0.66% | +437.74% | Jun 2026 |
| Renaissance Technologies Corp | 3.52M | 0.57% | -20.31% | Jun 2026 |
| Two Sigma Investments LLC | 3.51M | 0.57% | +49.90% | Jun 2026 |
| Harding Loevner L.P. | 3.09M | 0.50% | -4.50% | Jun 2026 |
| First Trust Advisors L.P. | 2.76M | 0.45% | +11.99% | Jun 2026 |
| Citadel Advisors Llc | 2.48M | 0.40% | 0.00% | Jun 2026 |
| Qube Research & Technologies | 1.69M | 0.27% | +149.40% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.63M | 0.27% | -25.38% | Jun 2026 |
| Federated Hermes Inc | 1.45M | 0.24% | +15.80% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.28M | 0.21% | +37.37% | Jun 2026 |
| Franklin Templeton Inc | 1.20M | 0.20% | +0.82% | Jun 2026 |
| Pictet Asset Manangement SA | 1.07M | 0.17% | -1.07% | Jun 2026 |
| UBS Group AG | 961K | 0.16% | +222.36% | Jun 2026 |
Genmab AS company profile
- Company name
- Genmab AS
- Ticker
- GMAB.US
- Exchange
- USA Stocks
- Listed since
- Jun 1, 2009
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,244
- Fiscal year end
- December
- Address
- Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
- Phone
- 45 70 20 27 28
- Website
- genmab.com
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Genmab AS management
10- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · born 1961
- Mr. Anthony Pagano CPAExecutive VP & CFO · born 1978
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · born 1968
- Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · born 1971
- Mr. Christopher CozicExecutive VP & Chief People Officer · born 1978
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · born 1971
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · born 1975
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · born 1958
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · born 1973
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · born 1973